MAP.AX - Microba Life Sciences Limited
| Previous close | 0.2700 |
| Open | 0.2750 |
| Bid | 0.2700 x N/A |
| Ask | 0.2750 x N/A |
| Day's range | 0.2700 - 0.2750 |
| 52-week range | 0.1350 - 0.4500 |
| Volume | |
| Avg. volume | 354,409 |
| Market cap | 94.637M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.30 |
GlobeNewswireMainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
Combination of DNA biomarkers with microbiome biomarkers has potential to enhance technical profile of novel pancreatic cancer screening test Joint research project to discover disease specific microbiome biomarkers BERKELEY, Calif. and MAINZ, Germany, May 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a research collaboration with Microba Life S
Business WireMicroba Launches Next Generation Healthcare Testing
BRISBANE, Australia, February 28, 2023--Microba Life Sciences Limited (ASX: MAP) ("Microba"), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™. This delivers on the new healthcare product launch milestone prefaced in the FY22 Annual Report and updated in quarterly reports following the closed beta release in June 2022.
Business WireSonic Healthcare Acquires Strategic Stake in Microba Life Sciences, Establishes Significant Commercial Partnership
BRISBANE, Australia, November 29, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) ("Sonic") has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba. In addition, Sonic is seeking to acquire options for an additional 5% equity position, subject to shareholder approval. Exercise of the options by Sonic would result in a further investment of $7.5m in Micr
Business WireSYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME
BRISBANE, Australia, October 27, 2022--SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.
Simply Wall St.We're Keeping An Eye On Microba Life Sciences' (ASX:MAP) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...